Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
John G. Morikis	Director Show All	Open Market Acquisition (Open Market Acquisition)	1.3K	0.000051%	208.7%	1.8K	206.2 - 206.2	257.7K	01 Dec 2025	26 Nov 2025 - 26 Nov 2025
John C. Reed	Executive Vice President of Innovative Medicine, R&D Show All	Derivative Exercise and Sale (Derivative Exercise and Sale)	-21.7K	-0.000901%	—	10.7K	157.9 - 192.7	-755.6K	20 Oct 2025	17 Oct 2025 - 17 Oct 2025
John C. Reed	Executive Vice President of Innovative Medicine, R&D Show All	Sale	-21.7K	—	—	—	192.7 - 192.7	-4.2M	17 Oct 2025	17 Oct 2025 - 17 Oct 2025
John G. Morikis	Director Show All	Initial Statement of Beneficial Ownership (Initial Statement of Beneficial Ownership)	—	—	—	599.0	—	—	15 Sep 2025	08 Sep 2025 - 08 Sep 2025
Marillyn A. Hewson	Lead Independent Director Show All	Other Derivative Acquisition (Other Derivative Acquisition)	281.0	—	2.1%	13.8K	—	—	11 Sep 2025	09 Sep 2025 - 09 Sep 2025
Daniel Eduardo Pinto
Eugene A. Woods
Jennifer L. Taubert
Jennifer L. Taubert
Elizabeth Forminard
Elizabeth Forminard
Elizabeth Forminard
Joaquin Duato
Joaquin Duato
Joseph J. Wolk
Joseph J. Wolk
John C. Reed
John C. Reed
Daniel Eduardo Pinto
Marillyn A. Hewson
Eugene A. Woods
John C. Reed
John C. Reed
Eugene A. Woods
Nadja Y. West
Mark Alan Weinberger
Mark B. McClellan
Hubert Joly
Paula A. Johnson
Marillyn A. Hewson